Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis

Mon Apr 15 07:01:55 2024

(2023) Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. Journal of Medical Virology. p. 9. ISSN 0146-6615

Full text not available from this repository.

Official URL: <Go to ISI>://WOS:000915761800001

Abstract

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for coronavirus disease 2019 (COVID-19). PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar were searched to identify the relevant evidence up to November 10, 2022. The reference lists of key studies were also scanned to find additional records. The quality of the studies was evaluated using the Cochrane tools for assessing the risk of bias. The Comprehensive Meta-Analysis software version 3.0 was employed for data analysis. Twenty-three studies involving 314 353 patients were included in the analysis. The findings of the meta-analysis showed a significant difference between the Paxlovid and no-Paxlovid groups in terms of mortality rate (odds ratio OR = 0.25; 95% confidence interval CI: 0.14-0.45), hospitalization rate (OR = 0.40; 95% CI: 0.24-0.69), polymerase chain reaction negative conversion time (mean difference MD = -2.46; 95% CI: -4.31 to -0.61), and hospitalization or death rate (OR = 0.17; 95% CI: 0.06-0.46). However, no significant difference was observed between the two groups in terms of COVID-19 rebound (OR = 0.84; 95% CI: 0.67-1.04), emergency department visit (OR = 0.75; 95% CI: 0.45-1.24), intensive care unit admission (OR = 0.37; 95% CI: 0.13-1.01), and adverse events (OR = 2.20; 95% CI: 0.42-11.47). The results of the present study support the efficacy and safety of Paxlovid in the treatment of patients with COVID-19. Further research is needed to investigate the COVID-19 rebound after Paxlovid treatment.

Item Type: Article
Creators:
CreatorsEmail
Amani, B.UNSPECIFIED
Amani, B.UNSPECIFIED
Keywords: COVID-19 nirmatrelvir/ritonavir Paxlovid SARS-CoV-2 molnupiravir Virology
Divisions:
Page Range: p. 9
Journal or Publication Title: Journal of Medical Virology
Journal Index: ISI
Volume: 95
Number: 2
Identification Number: https://doi.org/10.1002/jmv.28441
ISSN: 0146-6615
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4166

Actions (login required)

View Item View Item